What is the current stock price of Nuwellis, Inc. (NUWE)?

As of the latest market data, Nuwellis, Inc. (NUWE) is trading at $1.08. The stock has seen a gain of 0.46% today.

Does Nuwellis, Inc. (NUWE) pay a dividend?

Based on current data, Nuwellis, Inc. does not have a confirmed active dividend policy.

What is the market cap of Nuwellis, Inc.?

The current market capitalization of Nuwellis, Inc. (NUWE) is approximately unavailable.

NUWE

Nuwellis, Inc.·Healthcare

1.09

0.463%(+0.01)

Market Closed

1.34

23.502%(+0.26)

After Hours

Last Updated: — ET

52W L: $0.9652W H: $45.36

NUWE NEWS

globenewswire.com

2d ago

Nuwellis Engages CORE IR for Public Relations, Shareholder Communications, and Social Media Management Services

MINNEAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it has retained CORE IR, a leading investor relations, public relations, and strategic advisory firm, to assist the Company with public relations, shareholder communications, and social media management services.

globenewswire.com

4d ago

Nuwellis Strengthens Commercial Infrastructure with New South Texas Territory

Strategic expansion of field coverage enhances hospital engagement and increases access to Aquadex® therapy across the region Strategic expansion of field coverage enhances hospital engagement and increases access to Aquadex® therapy across the region

globenewswire.com

Mar 31

Nuwellis Pediatric Category Achieves Approximately 50% of Total U.S. Revenue in 2025, Marking Growth Milestone

Pediatric footprint expands to 47 centers nationwide, including six of the nation's top 10 children's hospitals Pediatric footprint expands to 47 centers nationwide, including six of the nation's top 10 children's hospitals

globenewswire.com

Mar 17

Nuwellis Completes Acquisition of Rendiatech

MINNEAPOLIS, March 17, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the completion of its previously announced acquisition of Rendiatech, Inc., an Israeli-based developer of automated kidney function monitoring technology designed to support clinical decision-making in critically ill patients. Rendiatech has no commercial operations and was formed to acquire certain assets of RenalSense Ltd.

seekingalpha.com

Mar 10

Nuwellis, Inc. (NUWE) Q4 2025 Earnings Call Transcript

globenewswire.com

Mar 10

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025.

Company Profile

Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

Sector

Healthcare

Industry

Medical - Devices

Employees

IPO Date

2012-02-16

Beta

0.08

Websitewww.nuwellis.com↗